Literature DB >> 3470166

Elimination of enoxacin in renal disease.

R W Bury, G J Becker, P S Kincaid-Smith, R F Moulds, J A Whitworth.   

Abstract

The elimination of enoxacin was investigated in 15 subjects, 10 of whom were hospital outpatients with renal disease and varying degrees of renal impairment. Each was given enoxacin orally (200 mg b.i.d.) for 7 days. Blood specimens collected over 24 hours after the final dose of enoxacin and urine collected during the 12-hour dose interval after the final dose were assayed for enoxacin by HPLC. The elimination half-life of enoxacin increased with worsening renal function. In general, patients with diminished renal function had lower plasma enoxacin clearance values than had normal subjects, and a statistically significant correlation between apparent oral clearance and creatinine clearance was observed. Excretion of enoxacin by the kidney accounted for 26% to 72% of the apparent plasma clearance in normal subjects. This was markedly reduced in patients with severe renal failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470166     DOI: 10.1038/clpt.1987.53

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 3.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.

Authors:  P Van der Auwera; J C Stolear; B George; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 5.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Effect of renal impairment on the pharmacokinetics of grepafloxacin.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli; J G Gambertoglio
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

7.  Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.

Authors:  C R Marchbanks; D J Mikolich; K H Mayer; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.